Respira Technologies, Inc. launches pharmaceutical focused commercial development platform to pursue API delivery partnerships with its proprietary RespiRx™ medical device platform
WEST HOLLYWOOD, Calif., June 2, 2020 /PRNewswire/ -- Respira Technologies, Inc., a health-technology platform development company, announced today the launch of its pharmaceutical focused commercial development program for the RespiRxTM drug delivery device platform.
- WEST HOLLYWOOD, Calif., June 2, 2020 /PRNewswire/ -- Respira Technologies, Inc., a health-technology platform development company, announced today the launch of its pharmaceutical focused commercial development program for the RespiRxTM drug delivery device platform.
- Respira Technologies' mission is to improve the standard of patient care and to improve public health outcomes by creating and commercializing cutting-edge drug delivery platforms.
- Danek created the ResipRxTM to be the first truly patient focused & ultra-portable handheld Vibrating Mesh Nebulizer (VMN) for local and systemic treatment.
- Respira has developed two proprietary platforms, an API agnostic drug delivery platform for water-soluble, thermosensitive drug compounds and a LOW-HEAT device platform for water-insoluble compounds.